New York S 4150: Relates to the availability of opioid reversal agents

Bill Text

Bill Search and Legislative Information | New York State Assembly 

• 

• 

• 

• 

• 

• 

• 

• 

 Skip to main content 

 New York State Assembly

 Speaker Carl E. Heastie

 --> 
 --> 

 --> 

• 
 Assembly Members 

• 
 Legislative Info 

• 
 Public Hearings 

• 
 Speaker's Press 

• 
 Assembly Reports 

• 
 Committees & More 

• Bill Search Home
• Laws
• Legislative Calendar
• Public Hearing Schedule
• Assembly Calendars
• Assembly Committee Agenda 

 Javascript must be enabled to properly view this page. 

 Bill No.: 

• Summary 
• Actions 
• Committee&nbspVotes 
• Floor&nbspVotes 
• Memo 
• Text 
• LFIN 
• Chamber&nbspVideo/Transcript 
S04150 Summary:

BILL NOS04150 

&nbsp

SAME ASSAME AS A00265-A

&nbsp

SPONSORHARCKHAM

&nbsp

COSPNSRADDABBO, ASHBY, COONEY, FAHY, GALLIVAN, OBERACKER, RYAN C, SEPULVEDA, SKOUFIS

&nbsp

MLTSPNSR

&nbsp

Amd §19.09, Ment Hyg L; amd §3309, Pub Health L

&nbsp

Relates to the availability of opioid reversal agents; requires the department of health to make available any formulation and dosage of opioid reversal agents approved by the federal food and drug administration.

Go to top S04150 Actions:

BILL NOS04150 

&nbsp

02/03/2025REFERRED TO ALCOHOLISM AND SUBSTANCE USE DISORDERS

01/07/2026REFERRED TO ALCOHOLISM AND SUBSTANCE USE DISORDERS

Go to topS04150 Committee&nbspVotes:

Go to topS04150 Floor&nbspVotes:

There are no Assembly votes for this bill in this legislative session.

Go to topS04150 Text:

 STATE OF NEW YORK
 ________________________________________________________________________

 4150

 2025-2026 Regular Sessions

 IN SENATE

 February 3, 2025
 ___________

 Introduced by Sens. HARCKHAM, ASHBY, COONEY, GALLIVAN, OBERACKER, SKOUF-
 IS -- read twice and ordered printed, and when printed to be committed
 to the Committee on Alcoholism and Substance Use Disorders

 AN ACT to amend the mental hygiene law and the public health law, in
 relation to the availability of opioid reversal agents

 The People of the State of New York, represented in Senate and Assem-
 bly, do enact as follows:

 1 Section 1. Subdivision (l) of section 19.09 of the mental hygiene law,
 2 as added by chapter 434 of the laws of 2021, is amended to read as
 3 follows:
 4 (l)(1) The office, in consultation with the department of health,
 5 shall maintain on its website a publicly available directory of all
 6 distributors of opioid [antagonists] reversal agents to the public,
 7 including but not limited to, pharmacies, prevention programs and not-
 8 for-profits. As used in this subdivision, the following terms shall have
 9 the following meanings:
 10 (i) "Opioid" means an opiate as defined in section thirty-three
 11 hundred two of the public health law.
 12 (ii) "Opioid [antagonist] reversal agents" means a federal food and
 13 drug administration-approved drug that, when administered, negates or
 14 neutralizes in whole or in part the pharmacological effects of an opioid
 15 in the body. The [opioid antagonist shall be limited to naloxone or
 16 other medications approved by the department of health for this purpose]
 17 department of health shall make available any formulation and dosage of
 18 opioid reversal agents that are approved by the federal food and drug
 19 administration.
 20 (iii) "Purchaser" means any community organization, municipality,
 21 pharmacy, medical facility, hospital, or any other entity, that accesses
 22 opioid reversal drugs through the New York state standing order.
 23 (2) The directory required by this subdivision shall include and be
 24 searchable by the following information:

 EXPLANATION--Matter in italics (underscored) is new; matter in brackets
 [ ] is old law to be omitted.
 LBD00351-03-5

 S. 4150 2

 1 (i) addresses of each distributor of opioid [antagonists] reversal
 2 agents;
 3 (ii) contact information, such as phone numbers or email addresses,
 4 for each distributor;
 5 (iii) services offered by each distributor at each location if more
 6 than one, as well as information providing which opioid [antagonists]
 7 reversal agents are currently available at each distributor;
 8 (iv) special populations served;
 9 (v) insurance providers accepted;
 10 (vi) hours of operation of each distributor;
 11 (vii) contact information of opioid addiction prevention programs; and
 12 (viii) any other information the commissioner deems necessary.
 13 (3) The office may utilize an existing directory to satisfy the
 14 requirements of this subdivision.
 15 (4) The office shall allow for choice of any formulation and dosage of
 16 opioid reversal agents that are approved by the federal food and drug
 17 administration in the purchase, distribution or authorization to
 18 prescribe or dispense such products. The department shall cover the cost
 19 of any formulation and/or dosage of any federal food and drug adminis-
 20 tration-approved nasal naloxone product. Any other product where the
 21 cost exceeds that of highest-priced nasal naloxone